Navigation Links
Opportunities Exist Despite Challenges in China's API Market
Date:11/6/2012

HANGZHOU, China, Nov. 6, 2012 /PRNewswire/ -- From 2002 to 2008, the average Chinese annual growth rate of APIs remained above 24%; in 2009, the total import & export value of APIs reached US$24.271 billion, with an increase of 2.89% year-on-year, which accounts for 49.42% of the total import & export value of Chinese pharmaceuticals. However, in the first three quarters in 2012, China's foreign trading has only increased by 1%-2%, indicating the coming of the most difficult trading time. As we all know, the competition in the global pharmaceutical APIs industry is very fierce and added with the slow global economic recovery, the European and American markets all have limited increases. Also, there is some uncertainty on the continuing increase in the newly emerging medical markets, and the demand in the international pharmaceutical market is not optimistic. All of these factors increase the risk of a downturn in the exporting of Chinese APIs.

Even so, LookChem still believes that the position of Chinese APIs will not be replaced in the global market in the short term. In China, there are more than 7,100 registered pharmaceutical production enterprises, with 4,000 more companies having obtained GMP certificates. There are also 1,600 more API industries that have registered with the SFDA and have the capacity to produce more than 1,600 products among 2,000 kinds of APIs. The number of API products which have obtained GMP certificates has now exceeded 3,700. At the same time, China's API market share occupies over 18% in the global market, ranking the first, while the generic APIs market share has reached above 35%. The international market still has rigid demand when compared with the Chinese API market, with many bulk drugs having some certain price advantages, including vitamin, penicillin, citric acid, antibiotics and acetaminophen.

Lianyungang Jinkang Pharmaceutical Technology Co., Ltd. is a professional company focused on pharmaceutical raw materials. In the environment of an inactive international market, this company is the one among the few large pharmaceutical raw material companies who have made its way into the international market, with the help of LookChem. It has been the largest supplier in European and American markets of calcium folinate, mesna, irinotecan, and gemcitabine, and its Pemetrexed Intermediate has obtained American patent licensing.

Zhejiang Aofutuo Chemical Co., Ltd., founded in 1993, is a national high-tech enterprise built on fine chemical products' R&D, production and management (mainly pharmaceuticals, pesticide intermediates). Dai Feng, General Manager & Chief Engineer, has been devoted to changing the status quo of Chinese agricultural chemicals, focusing on their development and the over-dependence on importing, with the aim of creating benefits for the Chinese people. After Mr. Dai lead the group to develop the new soil nitrating inhibition product – Nitrapyrin – the company has become the second enterprise after Dow Chemical to produce Nitrapyrin with a large-scale production capacity, which has been one good example of the growing strengths of China's pharmaceutical raw materials market.

There are many other pharmaceutical API enterprises who cooperate with LookChem. LookChem, being greatly concerned with the pharmaceutical APIs industry, has greatly promoted Chinese APIs to the international market. This chemical platform has helped enterprises to adapt to the national industrial transformation, including upgrades and high value-added exporting policy adjustments. It has also used funds to accelerate the construction of international APIs projects. Cooperating with foreign buyers, it has an in-depth understanding of the international market, and has lead the domestic suppliers to research the newest information and technological trends to develop high-performance & low-cost green products. It has also helped the industries to form the core competitiveness and build their own products and brands specifically for their own target customers.

At the same time, LookChem has assisted the domestic pharmaceutical API industries to establish a marketing network suited for the international development of products, and perfect the product supply chain. This has helped enhance the international reputation of the industries and their products, and accelerated the pace of international certification. All of these help promote the internationalization and development of Chinese pharmaceutical APIs.

Currently, the Chinese pharmaceutical APIs market, although being struck to some certain extent, still has opportunities, and this is also another chance for the APIs industry to raise their strength. As for LookChem, for having always been optimistic about the pharmaceutical APIs market, will make all its efforts to increase the market share in this domain.


'/>"/>
SOURCE LookChem
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. LABSCO Implements Leading-Edge Technology to Support Growth and Seize Opportunities in the Clinical Laboratory Market
2. Transdermal Pain Management to 2016: Products, Markets, Forecasts and Opportunities
3. Branded Generics in South East Asia: Current and Future Opportunities
4. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
5. STAAR Surgical Builds Leadership Team to Drive Growth Opportunities
6. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
7. Meridian Labs Hires Investment Bank to Explore Strategic Opportunities
8. Wound Care Management Market to 2018 - Advanced Wound Care Modalities and an Expanding Patient Base Create Significant Growth Opportunities in Emerging Countries
9. Neura Therapeutik Forms Business Units to Pursue Analgesic Market Opportunities
10. Alternate Distribution Channels Claim Opportunities for OTC Drug Sales in the United States, Finds Kline
11. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):